BioXcel Therapeutics effectuates 1-for-16 reverse stock split effective Feb 7, 2025

BioXcel Therapeutics, Inc.

Board approved 1-for-16 reverse split on Jan 29; stockholders approved at Jan 28 special meeting.
Every 16 shares of common stock reclassified into 1 share; no fractional shares, cash paid for fractions.
Split-adjusted trading begins Feb 10 under existing symbol BTAI; new CUSIP 09075P204.
Proportional adjustments to equity plans, stock options, warrants, and other convertible securities.
Reverse split does not affect authorized shares or par value; shares remain fully paid and non-assessable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.